- Aug 5, 2004
Luvox, a SSRI for OCD, may help prevent COVID-19 from getting worse due to its anti-inflammatory effects. The first results of a national trial should available next month. Based on small, preliminary trial, the director of the NIH says that doctors may want to consider Luvox as a "tool in their tool chest."
Similarly with other SSRIs like Prozac:Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19.www.cbsnews.com
Dr. Reiersen remembered a study published a year earlier by these researchers at the University of Virginia on mice. They found fluvoxamine stopped sepsis. Sepsis is a runaway immune response in which inflammation gets out of control, damages organs and can be deadly. It's believed a similar phenomenon occurs in COVID patients...
Sharyn Alfonsi: You thought, this is something that might be able to stop inflammation from going into overdrive?
Dr. Angela Reiersen: Right. Either stop the inflammation from going into overdrive or shut it down once it had started to prevent our own bodies from destroying ourselves basically.
Two psychiatrists had a theory, and with support from a Silicon Valley philanthropist they've published some encouraging findings.www.latimes.com
“My hypothesis in early March was that … antidepressants including fluvoxamine and fluoxetine could work for COVID because of their anti-inflammatory and potentially antiviral properties,” said Dr. Nicolas Hoertel, associate professor of psychiatry at Paris University and a psychiatrist at a hospital just outside the city.
“I also noticed at this time that almost no patients with psychiatric disorders hospitalized in my unit had symptomatic COVID, whereas many caregivers had COVID symptoms in the unit,” Hoertel said.